Scienture Holdings, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsScienture Holdings, Inc. is a specialty pharmaceutical company focused on commercializing products for hypertension and opioid overdose, with a pipeline in CNS and CVS diseases.
What they do
Scienture Holdings, Inc., through its wholly-owned subsidiary Scienture, LLC, develops, commercializes, and distributes novel specialty pharmaceutical products. It has launched ARBLI (losartan potassium oral suspension) for hypertension and is commercializing REZENOPY (naloxone HCl nasal spray) for opioid overdose. The pipeline includes candidates for migraine, thrombosis, pain, and other related disorders. The company divested its legacy businesses (Softell, IPS, Bonum Health) in April 2025 to focus on branded and specialty pharma.
Revenue drivers
- ARBLI (SCN-102) — Commercial hypertension product; Q1 2026 revenue was $56 thousand, up 449% from $10 thousand in Q1 2025, reflecting incremental product orders after initial launch quantities in Q4 2025.
- REZENOPY (naloxone HCl nasal spray) — Second product in commercialization for opioid overdose; has secured GPO agreements reaching ~60% of U.S. institutional market, but no revenue yet as launch is pending.
- Development pipeline — Novel product candidates for migraine, thrombosis, pain, and other disorders; not yet generating revenue but represent future growth potential.
Recent performance
For Q1 2026, revenue increased 449% year-over-year to approximately $56 thousand, with gross profit of approximately $54 thousand and gross margin of 95.6%, versus 6.6% in Q1 2025. Quarterly revenue was $343,639 for Q2 2026 (three months ended June 30, 2026), up from $56,325 in Q1 2026. Full-year 2025 revenue was $431,609, with net income of $-41.5M and diluted EPS of $-2.70. Cash and equivalents were $8.2M as of June 30, 2026, with total assets of $87.7M and shareholder equity of $64.1M.
Strategy
The company is focused on advancing its commercial products and pipeline through clinical studies toward FDA approval. It plans to drive growth and profitability using dedicated sales and marketing resources, with a sales force scheduled to begin operations June 1, 2026 to target key accounts and purchasing organizations. Management aims to expand ARBLI market penetration through enhanced promotional activities and to support the launch of REZENOPY via secured GPO contracts. The company also secured $11 million in non-dilutive debt financing (April 2026) to accelerate growth and R&D.
Risks
- Limited revenue base — Revenue is minimal (e.g., $56K in Q1 2026) and highly dependent on early commercialization of ARBLI and future launch of REZENOPY.
- Dependence on FDA approvals — Pipeline candidates are at various stages of clinical development and require FDA approval before commercialization, which may not be obtained on expected timelines.
- Cash burn and financing risk — Operating cash flow was negative $13.4M in 2025 and $14.3M in 2024, and with only $8.2M cash, the company may need additional capital to fund operations.
- Competitive and market adoption risk — REZENOPY faces existing naloxone products; success depends on market adoption, GPO execution, and sales force effectiveness.
Outlook
Management expects continued month-over-month growth in prescriptions and units sold for ARBLI and anticipates the launch of REZENOPY will have a meaningful impact in the second half of 2026. The company believes the $11 million debt financing strengthens its capital position and supports scaling commercial operations, with a goal toward profitability in 2027. It is actively working on commercial initiatives to increase physician awareness and secure broad market access.